NASDAQ OMX

DNA announces the preliminary price range for its planned IPO

Dela

DNA OYJ PRESS RELEASE 14 NOVEMBER 2016, 4:00 pm EET

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE
OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

This document is an announcement and not a prospectus for the purposes of applicable measures implementing EU Directive 2003/71/EC as amended (such Directive, together with any applicable implementing measures of the relevant Member State under such Directive, the "Prospectus Directive") and as such does not constitute an offer to sell or the solicitation of an offer to purchase securities. Investors should not subscribe for, or purchase, any securities referred to in this document except on the basis of the information in the prospectus, prepared pursuant to the Prospectus Directive, in connection with the proposed listing of ordinary shares in the share capital of the Company on Nasdaq Helsinki Ltd (the "Prospectus"), which will be approved by the Finnish Financial Supervisory Authority and published in due course.

DNA Oyj ("DNA" or the "Company"), a Finnish full service telecommunications operator, today announces the preliminary price range for its planned initial public offering ("IPO" or the "Offering"). The Company announced on 26 October 2016 that it was planning an IPO on the official list of Nasdaq Helsinki Ltd (the "Helsinki Stock Exchange"). The subscription period for the IPO commences tomorrow 15 November 2016 at 10:00 EET.

The IPO in brief

  • The preliminary price range in the IPO is EUR 9.85 - 11.15 per share (the "Preliminary Price Range").

  • The implied market capitalization of the Company based on the Preliminary Price Range is approximately EUR 1.30 - 1.47 billion, assuming that gross proceeds of EUR 50 million are raised in the Offering from the offering of new shares by the Company.

  • The Offering:

    • The Company aims to raise gross proceeds of approximately EUR 50 million by offering new shares ("New Shares") for subscription ("Share Issue"). The Share Issue also includes a Personnel Offering (as defined below).

    • Preliminary up to 35,950,000 existing shares in the Company (the "Sale Shares, together with the New Shares, the "Offer Shares") are being offered for sale by certain existing shareholders of the Company (the "Sellers") (the "Share Sale", together with the Share Issue, the "Offering"). Of the Sale Shares, up to 19,110,655 shares are being offered for sale by Finda Oy and up to 13,578,345 shares by PHP Holding Oy (Finda Oy and PHP Holding Oy together the "Institutional Sellers").

    • Over-Allotment Option (as defined below) of a maximum of 6,064,100 shares shall be given to the Stabilising Manager (as defined below) by the Institutional Sellers.

    • The Offering consists of (i) a public offering to private individuals and entities in Finland (the "Public Offering"), (ii) personnel offering to the Personnel (as defined below) (the "Personnel Offering") and (iii) private placements to institutional investors in Finland and internationally (the "Institutional Offering").

  • Based on the Preliminary Price Range, and assuming that New Shares corresponding to gross proceeds of EUR 50 million are subscribed for in the Share Issue, of which a total of 50,000 New Shares are subscribed for in the Personnel Offering, the maximum amount of Sale Shares are sold in the Share Sale, and that the Over-Allotment Option is exercised in full, the IPO is valued at approximately EUR 464 - 518 million.

  • The post-IPO free float is expected to be approximately 35 percent of the Company's shares, assuming that the Final Offer Price (as defined below) is at the mid-point of the Preliminary Price Range, New Shares corresponding to gross proceeds of EUR 50 million are subscribed for in the Share Issue, of which a total of 50,000 New Shares are subscribed for in the Personnel Offering, the maximum amount of Sale Shares are sold in the Share Sale and the Over-Allotment Option is exercised in full. The Institutional Sellers will together retain 55 percent ownership of the Company after the Offering assuming full exercise of the Over-Allotment Option.

  • The subscription period for the Public Offering and Personnel Offering will commence on 15 November 2016 at 10:00am EET and end on 25 November 2016 at 4:00pm EET, unless the subscription period is discontinued or extended.

  • The subscription period for the Institutional Offering will commence on 15 November 2016 at 10:00am EET and end on 29 November 2016 at 12:00 noon EET, unless the subscription period is discontinued or extended.

  • Trading in the Offer Shares is expected to begin on the Pre-List of the Helsinki Stock Exchange on or about 30 November 2016 and on the official list of the Helsinki Stock Exchange on or about 2 December 2016 and the shares will trade under the share trading code "DNA".

Jukka Leinonen, CEO of DNA:

"I am very pleased with the response we have received from investors after we announced our intention to float our shares on the Helsinki Stock Exchange. The successful implementation of our strategy and the development opportunities going forward have attracted considerable interest. Committed shareholders and motivated personnel have built DNA into a strong Finnish telecommunications service provider of DNA. We have a solid base to further develop our business and create value for our new shareholders. DNA is ready to move to a new phase and continue its operations as a publicly listed company."

Background and reasons for the IPO

DNA is one of the leading telecommunication service providers in Finland. The Company has its own nationwide mobile communication network and the largest hybrid-fibre coaxial network, which enable the company to provide high quality voice, data and TV services to its customers. The Company's business is divided into consumer and business segments. DNA has over 3.8 million subscription customers in total and it employs approximately 1,700 telecommunications professional whose focus is in providing excellent customer experiences in accordance with DNA's strategy.

DNA's strategic focus will be on achieving the most satisfied customers in the market by aiming to provide high quality, fairly priced and easy to use mobile services, mobile and fixed broadband services and TV and video services. The Company aims to leverage its competitive mobile infrastructure that will allow it to continue providing the fastest and the highest quality services in the market and consequently translate into high customer satisfaction and continued sales growth. DNA also intends to capitalise on significant upselling and cross-selling opportunities in the Consumer segment by leveraging its strong market positions and converged service offering, while the Company's multi-platform TV strategy allows a high quality TV and video offering across all devices. In the Corporate segment, DNA's strategy is to increase its market share and profitability by leveraging its state-of-the-art networks and high customer satisfaction in different product categories. The Company aims to continue cost and capital expenditure control and carry on operational efficiency initiatives to further enhance cash flow generation of the business.

The objective of the Offering is to position DNA for its next development phase. The initial public offering will enable DNA to obtain access to capital markets, expand its ownership base and increase the liquidity of the Shares. Additional visibility provided by the IPO is also expected to increase DNA's recognition among the public and as an employer, and thus enhance the Company's competitiveness.

Details of the IPO

In the IPO, preliminarily a maximum of 1,000,000 Offer Shares are offered to private individuals and entities in Finland and 39,981,143 Offer Shares to Finnish and international institutional investors, assuming that the Over-Allotment Option is not exercised. In the Personnel Offering, the Company offers for subscription a maximum of 50,000 New Shares and, in the event of an oversubscription, a maximum of 250,000 additional New Shares ("Personnel Shares") to all permanent or fixed-term employees of the Company or its wholly-owned subsidiaries in Finland and all agency employees who work at the Company or its wholly-owned subsidiaries in Finland during the subscription period, the members of the Board of Directors of the Company and the CEO of the Company ("Personnel").

With the Share Issue, the Company aims to raise gross proceeds of approximately EUR 50 million. The number of New Shares to be issued will be determined based on the Final Offer Price. The Company would issue 4,766,905 New Shares assuming that the Final Offer Price for the New Shares would be at the mid-point of the Preliminary Price Range and total of 50,000 New Shares would be subscribed in the Personnel Offering at a discount applicable to such New Shares. Preliminarily up to 35,950,000 Sale Shares are being offered for sale by existing shareholders of the Company. DNA expects to use net proceeds from the Share Issue to strengthen its capital structure and maintain financial flexibility to carry out disciplined growth investments and possible selective value creative M&A. Additionally, the proceeds will give DNA sufficient financial flexibility for a possible bid in the forthcoming 700 MHz spectrum auction.

The Offer Shares represent approximately 30.8 percent of the Company's shares (the "Shares") and votes after the Share Issue without the Over-Allotment Option (with the Over-Allotment Option approximately 35.4 percent) assuming that the Sellers sell the maximum amount of Sale Shares and that the New Shares issued by the Company equal, as stated above, 4,766,905 New Shares.

In the event the number of New Shares issued in the Share Issue is 4,766,905 as mentioned above, the number of shares outstanding after the offering would amount to 132,092,755 Shares, of which the Institutional Sellers together would hold 59.5 percent, assuming that the Sellers would sell the maximum amount of Sale Shares and the Over-Allotment Option is not exercised. If the Over-Allotment Option is exercised, the Institutional Sellers together would hold 54.9 percent. Furthermore, all Sellers will agree, subject to certain exceptions, not to divest their shares held at admission for a period of 360 days from the listing of the Company.

The preliminary price range for the Offer Shares in the Institutional Offering and Public Offering is a minimum of EUR 9.85 and a maximum of EUR 11.15 per Offer Share. The final price per Offer Share (the "Final Offer Price") will be communicated through a stock exchange release on or about 29 November 2016. The Final Offer Price may also be above or below the Preliminary Price Range provided, however, the Final Offer Price in the Public Offering shall not be higher than the maximum of the Preliminary Price Range, EUR 11.15 per Offer Share. The subscription price per share in the Personnel Offering is 10 percent lower than the Final Offer Price in the Public Offering.

The Institutional Sellers and Danske Bank A/S, Helsinki branch, in its capacity as stabilising manager (the "Stabilising Manager") may agree that the Institutional Sellers shall give the Stabilising Manager an over-allotment option exercisable within 30 days from the commencement of trading of the Shares on the Helsinki Stock Exchange (which is estimated to occur between November 30, 2016 and December 29, 2016), to purchase or to procure purchasers for a maximum of 6,064,100 additional shares solely to cover over-allotments (the "Over-Allotment Option"). The Shares included in the Over-Allotment Option represent approximately 4.6 percent of the shares and votes after the Share Issue, assuming that the Sellers sell the maximum amount of Sale Shares and that the Company issues 4,766,905 New Shares (the number of New Shares is calculated assuming that the Final Offer Price would be at the mid-point of the Preliminary Price Range and total of 50,000 New Shares would be subscribed in the Personnel Offering at a discount applicable to such New Shares).

Danske Bank A/S, Helsinki branch and Morgan Stanley & Co. International plc are acting as joint global coordinators in the IPO, and J.P. Morgan Securities plc, Nordea Bank Finland Plc and Skandinaviska Enskilda Banken Ab (publ), Helsinki branch are acting as joint bookrunners. Lazard & Co Ltd is the financial advisor to the Company. Castrén & Snellman Attorneys Ltd and Skadden, Arps, Slate, Meagher & Flom (UK) LLP are acting as legal advisers to the Company. Borenius Attorneys Ltd and Shearman & Sterling (London) LLP are acting as legal advisers to the joint global coordinators and joint bookrunners.


Preliminary timetable (all times are Finnish time)

Subscription period of the Offering commences November 15, 2016
10:00 am
The Offering may be discontinued at the earliest November 22, 2016
4:00 pm
Subscription period of the Public Offering and Personnel offering ends on or about November 25, 2016
4:00 pm
Subscription period of the Institutional Offering ends on or about November 29, 2016
12:00 noon
Announcement of the final results of the Offering on or about November 29, 2016
New Shares subscribed for in the Public Offering registered in the investors' book-entry accounts on or about November 30, 2016
Trading in the Shares, excluding Personnel Shares, commences on the pre-list of the Helsinki Stock Exchange on or about November 30, 2016
Trading in the Shares, excluding Personnel Shares, commences on the official list of the Helsinki Stock Exchange on or about December 2, 2016
The Offer Shares offered in the Institutional Offering are ready to be delivered against payment through Euroclear Finland on or about December 2, 2016
Personnel Shares subscribed for in the Personnel Offering registered in the Trade Register on or about December 16, 2016
Personnel Shares subscribed for in the Personnel Offering registered in the subscribers' book-entry accounts on or about December 16, 2016
Trading in the Personnel Shares commences on the official list of the Helsinki Stock Exchange on or about December 16, 2016

The Finnish Prospectus
The Company has submitted a Finnish language prospectus ("Finnish Prospectus") for approval with the Finnish Financial Supervisory Authority, and it is expected to be approved today 14 November 2016. The information stated in this press release regarding the Offering are conditional upon the approval of the Finnish Prospectus by the Finnish Financial Supervisory Authority today 14 November 2016. The Finnish Prospectus and a Finnish language marketing brochure will be available in electronic format on the Company's website at www.dna.fi/listautumisanti no later than 15 November 2016 before the start of the subscription period. Printed versions of the Finnish Prospectus and marketing brochure are expected to be available no later than 17 November 2016 and can be obtained from the Company's headquarters (Läkkisepäntie 21, 00620 Helsinki), branch offices of Danske Bank and Nordea as well as at the Helsinki Stock Exchange (Fabianinkatu 14, 00100 Helsinki).

Further information on the IPO, including places of subscription, can be obtained from www.dna.fi/listautumisanti, www.danskebank.fi, www.nordea.fi and from the branch offices of Danske Bank and Nordea.

Proposed dividend to be paid for the financial year 2016

DNA announced on 26 October 2016 that the Company's Board of Director's conditional decision is to propose to the annual general meeting of the Company to be held in 2017 that a total dividend of approximately EUR 70 million is to be paid for the financial year 2016. Based on the prior decision, the Board of Directors has made a conditional decision that it will propose to the annual general meeting of the Company to be held in 2017 that a EUR 0.55 dividend per share shall be paid for the financial year 2016 assuming the Company's financial standing permits distributing dividends.

Further enquiries
Jukka Leinonen, CEO, DNA Oyj, tel. +358 44 044 1000, jukka.leinonen@dna.fi
DNA Corporate Communications, tel. +358 44 044 8000, communications@dna.fi

Disclaimer
The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

This document is not an offer for sale nor a solicitation of an offer to buy any securities in the United States (including any of its states, its territories and possessions and the District of Columbia). These materials are not for distribution, directly or indirectly, in or into the United States. The securities referred to herein (the "Securities") have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the laws of any state of the United States. Consequently, the Securities may not be offered, sold, pledged or otherwise transferred directly or indirectly in or into the United States except in accordance with the registration requirements of the Securities Act or an exemption therefrom. No public offering of the Securities is being made in the United States.

This document is an announcement and not a prospectus for the purposes of applicable measures implementing EU Directive 2003/71/EC as amended (such Directive, together with any applicable implementing measures of the relevant Member State under such Directive, the "Prospectus Directive") and as such does not constitute an offer to sell or the solicitation of an offer to purchase securities. Investors should not subscribe for, or purchase, any securities referred to in this document except on the basis of the information in the prospectus, prepared pursuant to the Prospectus Directive, in connection with the proposed listing of ordinary shares in the share capital of the Company on Nasdaq Helsinki Ltd (the "Prospectus"), which will be approved by the Finnish Financial Supervisory Authority and published in due course.

A prospectus prepared pursuant to the Prospectus Directive and the Finnish Securities Markets Act (746/2012, as amended) on the public offering of securities and the admission of securities to trading on a regulated market (the "Prospectus Law") will be approved by the Finnish Financial Supervisory Authority and published which, when published, will be made available in accordance with the requirements of the Prospectus Directive and the Prospectus Law in Finland and can be obtained from the Company and other placed indicated in the Prospectus.

The securities referred to herein are not and will not be publicly offered, sold or registered, in any jurisdiction other than Finland. Any offer of securities to the public that may be deemed to be made pursuant to this communication in any EEA Member State other than Finland is addressed solely to qualified investors (within the meaning of the Prospectus Directive) in that Member State.

The joint global coordinators and the joint bookrunners are each acting exclusively for the Company and for no-one else in connection with any transaction mentioned in this announcement and will not regard any other person (whether or not a recipient of this announcement) as a client in relation to any such transaction and will not be responsible to any other person for providing the protections afforded to their respective clients, or for advising any such person on the contents of this announcement or in connection with any transaction referred to in this announcement. The contents of this announcement have not been verified by the joint global coordinators or joint bookrunners.

This announcement does not constitute a recommendation concerning the offering. The price and value of securities and any income from them can go down as well as up. Past performance is not a guide to future performance. Information in this announcement or any of the documents relating to the offering cannot be relied upon as a guide to future performance. There is no guarantee that the listing on the Helsinki Stock Exchange will occur and you should not base your financial decisions on the Company's intentions in relation to the listing at this stage. Potential investors should consult a professional advisor as to the suitability of the offering for the entity concerned.

Each of the joint global coordinators and joint bookrunners and any of their respective affiliates, acting as investors for their own accounts, may purchase shares and in that capacity may retain, purchase, sell, offer to sell or otherwise deal for their own accounts in such shares and other securities of the Company or related investments in connection with the offering or otherwise. Accordingly, references in the final prospectus, once published, to the shares being offered, acquired, sold, placed or otherwise dealt in should be read as including any offer, sale, acquisition, placing or dealing in the shares by any of the joint global coordinators and joint bookrunners and any of their affiliates acting as investors for their own accounts. In addition, certain of the joint global coordinators or joint bookrunners or their affiliates may enter into financing arrangements and swaps in connection with which they or their affiliates may from time to time acquire, hold or dispose of shares. None of the joint global coordinators or joint bookrunners intends to disclose the extent of any such investment or transaction otherwise than in accordance with any legal or regulatory obligations to do so.

No representation or warranty, express or implied, is given by or on behalf of the joint global coordinators or joint bookrunners or any of their respective subsidiaries, affiliates, agents or advisers or any of such persons' affiliates, directors, officers or employees or any other person as to the fairness, truth, accuracy, completeness or verification of the information or the opinions contained in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available, and no liability is accepted for any such information, omissions or opinions. Each of the joint global coordinators and joint bookrunners or any of their respective subsidiaries, affiliates, agents or advisers or any of such persons' affiliates, directors, officers or employees or any other person disclaim any and all responsibility and liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this announcement or its contents or otherwise in connection with this announcement.

Lazard, which is authorised and regulated by FCA, is acting exclusively for the Company and no one else in connection with the potential offering and will not regard any other person as its client in relation to the potential offering and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for giving advice in relation to the proposed offering or the contents of this announcement or any transaction, arrangement or other matter referred to herein.

This communication does not constitute an offer of the Securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the Securities. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.

Shares in the Company have not been and will not be registered under the applicable securities laws of Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or Singapore and, subject to certain exceptions, may not be offered or sold within Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or Singapore or to, or for the account or benefit of, citizens or residents of Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or Singapore except under circumstances which will result in full compliance with the applicable laws and regulations promulgated by the relevant regulatory authorities in effect at the relevant time.

Forward looking statements
Certain statements in this press release are not historical facts and are "forward looking" within the meaning of Section 27A of the U.S. Securities Act and 2(1)(e) of the U.S. Securities Exchange Act of 1934. Forward looking statements include statements concerning our plans, expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, our competitive strengths and weaknesses, plans or goals relating to financial position, future operations and development, our business strategy and the trends we anticipate in the industries and the political and legal environment in which we operate and other information that is not historical information, such as potential dividend payments, price range of the Offering and stabilisation of the contemplated IPO and listing. In some instances, they can be identified by the use of forward-looking terminology, including the terms "believes", "intends", "may", "will" or "should" or, in each case, their negative or variations on comparable terminology. By their very nature, forward looking statements involve inherent risks, uncertainties and assumptions, both general and specific, and risks exist that the predictions, forecasts, projections and other forward looking statements will not be achieved. Given these risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward looking statements. Any forward looking statements contained herein speak only as at the date of this document. Save as required by law, the Company, the joint global coordinators or the joint bookrunners do not intend and do not assume any obligation, to update any forward looking statement contained herein.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DNA Oyj via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

GridGain® Continues In-Memory Computing Industry Leadership in 201818.7.2018 09:00Pressmeddelande

GridGain Continues Rapid Growth, Delivers Product Innovations, Hosts Vital Industry Conferences and Earns Top Industry Accolades FOSTER CITY, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite(TM), today announced continuing strong momentum for the first half of 2018. Key achievements during the first half of the year included more new customer wins in the first half of 2018 than in all of 2017, launching major new products including GridGain Professional Edition 2.4 and GridGain Cloud, winning several top industry accolades, and driving continued growth of the popular In-Memory Computing Summit® in Europe. Growth New customer acquisition surged during the first half of 2018 with the company acquiring 40 percent more new customers than were signed in all of 2017. New customers acquired in 2018 include leading companies in financial services, transportation, telecommunications, retail, healthcar

Cryptomining Replaces Ransomware as Most Popular Cybercrime Malware18.7.2018 09:00Pressmeddelande

Analysis of vulnerability and threat trends shows cryptomining malware dominates threat landscape in the first half of 2018 SAN JOSE, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Skybox® Security, a global leader in cybersecurity management, announced today the release of its mid-year update to the Vulnerability and Threat Trends Report which analyzes vulnerabilities, exploits and threats in play. The report, compiled by the team of security analysts at the Skybox® Research Lab, aims to help organizations align their security strategy with the reality of the current threat landscape. The mid-year update explores trends observed from January to June of 2018. One of the most significant findings is the replacement of ransomware as the cybercriminal tool of choice with cryptomining malware. In the last six months of 2017, ransomware accounted for 32 percent of attacks, while malicious cryptominers accounted for seven percent. By the first half of 2018, the figures had switched almost exactly

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30Pressmeddelande

LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma

Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15Pressmeddelande

BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio

Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05Pressmeddelande

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00Pressmeddelande

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum